The SURMOUNT-3 trial article (linked elsewhere in this document!) has much information on weight loss t results and reduction in waist circumference, with great visual aids illustrating findings on this and other topics.
Clinical trials are ongoing to uncover more. One is not even testing doses less than the 10mg.
Can New Weight-Loss Drugs Really Treat Obesity?
Yale Medicine, June 2022
https://www.yalemedicine.org/news/new-medications-treat-obesity
SURMOUNT-1: Tirzepatide Drastically Reduces Weight in Obese Patients
TCT MD, June 2022
https://www.tctmd.com/news/surmount-1-tirzepatide-drastically-reduces-weight-obese-patients
Anti-obesity drug discovery: advances and challenges
Nature reviews Drug Discovery, 2022
Efficacy of GLP-1 Agonists for Weight Loss in Adults Without Diabetes Clinical Advisor June, 2022
Glucagon, GLP-1 and Thermogenesis
Int J Mol Sci. 2019
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678955/
The Case for Early Use of Glucagon-like Peptide-1 Receptor Agonists in Obstructive Sleep Apnea Patients with Comorbid Diabetes and Metabolic Syndrome
Life (Basel). 2022 August